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 Rho inhibition promotes vemurafenib resistance in BRAF mutant melanoma 
 
 
Abstract 
Current treatments for patients with BRAF mutated melanoma show limited success 
utilizing the drug vemurafenib by only temporarily stopping cancer cell growth. 
Eventually BRAF mutated cells come back completely resistant to vemurafenib. The 
mechanisms behind emerging resistance are not well understood, yet studies suggest 
that actin polymerization through Rho small family GTPase signaling have an important 
role. In an attempt to address this working hypothesis we created an in vitro model using 
the A375 cell line and treated the cells with vemurafenib combined with RNAi 
knockdowns of Rho or using a drug named fasudil, which inhibits ROCK kinase a 
downstream target of Rho. Our data showed that through either direct or indirect Rho 
pathway inhibition there was a promotion of acquired resistance in the A375 cell line. 
Additionally we see an up regulation of transcription factors Yap/Taz and increased 
protein expression of pPaxillin Y31, pMEK S217, and pMEK S298. All of these proteins 
have been associated with Rac1 activity or BRAF activity within the cell. The increase in 
Rac1 activity may help give us a better explanation of what cellular pathways BRAF 
mutated cells utilize to promote resistance. 
 
Introduction 
Identification of a major mutation, BRAFV600E, in cutaneous melanoma patients was a 
major breakthrough in the search for effective clinical treatments for this deadly disease. 
This non-conservative mutation of valine to glutamic acid at the 600 position of the 
BRAF protein is present in approximately 50% of all skin melanomas.1-4 Current 
treatments for BRAF mutant melanoma utilize the drug vemurafenib, which acts as a 
BRAF kinase inhibitor. Vemurafenib treatment significantly prolongs survival times in 
patients with the BRAFV600E mutation; however, resistant cells eventually emerge in 
patients and tumors typically come back within ~6 months. 5-7 There is evidence that Rho 
family small GTPases may play significant roles in acquired resistance to vemurafenib.8 
When Rho is in it’s active, GTP-bound form it signals to a downstream effector called 
ROCK kinase. ROCK kinase acts as a key regulator for actin polymerization in the cell 
and plays a role in cell migration.9 Previously published research suggests that inhibition 
of actin remodeling can potentially suppress acquired resistance to vemurafenib.10 In 
preliminary experiments we developed an vitro model of acquired resistance using 
BRAFV600E mutant A375 melanoma cells. In A375 cells, Rho GTPase signaling was 
then either directly inhibited through RNAi knockdowns of RhoA/C or indirectly inhibited 
through ROCK kinase utilizing the drug fasudil. Resulting data illustrated that 
vemurafenib and inhibition of Rho signaling caused acquired resistance to emerge in a 
shorter time than vemurafenib-only treated cells. This recently obtained data suggests 
that suppressing RhoA/C signaling promotes acquired resistance, possibly by up 
regulating the activity of other Rho family small GTPases.  Exploring other small 
GTPases such as Rac1 could reveal a possible explanation. Rac1 also plays a role in 
actin polymerization and signals to a downstream effector PAK1 that plays a similar role 
to ROCK kinase, acting as a key regulator of actin polymerization.11 Further investigation 
of which Rho family GTPases may be the major contributors to acquired resistance 
could potentially fill the gap in previous knowledge towards what causes the emerging 
resistance in vemurafenib treated cells. 
 
 Methods 
Cell Culture 
A375 cells were thawed from liquid nitrogen then passaged in standard DMEM growth 
medium supplemented with 10% fetal bovine serum, 1% non-essential amino acids, 1% 
glutamine, 1% pen strep. Cells were then incubated at 37°C for propagation. 
 
 
In vitro growth assays 
RhoA/RhoCsh1 and RhoA/RhoCsh2 knockdown assay 
RhoAsh1, RhoCsh1, RhoAsh2, and RhoCsh2 were treated with DMSO or 3 mM 
vemurafenib. A standard DMEM growth medium supplemented with 10% fetal bovine 
serum, 1% non-essential amino acids, 1% glutamine, 1% pen strep was added to make 
volume 2 ml total. The cells were re-fed with their respective drug concentrations and re-
seeded to 40,000 every four days. The cells were harvested, counted, and recorded 
accordingly at every four-day time point as well. The cells were left growing until 60 
days. 
 
A375 fasudil assay 
A total of 40,000 A375 cells per well were plated in a six well plate and were treated with 
DMSO, 3 mM vemurafenib, 10 mM fasudil, or 3 mM vemurafenib and 10 mM fasudil. A 
standard DMEM growth medium supplemented with 10% fetal bovine serum, 1% non-
essential amino acids, 1% glutamine, 1% pen strep was added to make volume 2 ml 
total. The cells were re-fed with their respective drug concentrations and re-seeded to 
40,000 every four days. The cells were harvested, counted, and recorded accordingly at 
every four-day time point as well. The cells were left growing until 65 days. 
 
A375 fasudil assay lysate setup 
A375 cells from a 100% confluent T75 ml flask were harvested with 10% being placed 
into a 60mm dish with DMSO or 10 mM fasudil and 40% being placed into a 60mm dish 
with 3 mM vemurafenib or 3 mM vemurafenib + 10 mM fasudil. Two extra 60mm dishes 
were made for vemurafenib and vemurafenib + fasudil conditions. A standard DMEM 
growth medium supplemented with 10% fetal bovine serum, 1% non-essential amino 
acids, 1% glutamine, 1% pen strep was added to make volume 4 ml total. Cells were re-
feed every four days and cells were lysed at 4 days, 14 days, or 30 days to be 
immunoblotted. 
 
Immunobloting  
Cells were rinsed with 20 mm HEPES, pH 7.5, 150 mm NaCl, 5 mm MgCl2 (HBSM) and 
lysed in 1X SDS laemmli buffer. The lysates were scraped, boiled, and sheared using 
27G1/2 needle. The protein concentration was evaluated using Red 660 Protein Assay 
(G Biosciences #786-676). Normalized protein lysates were resolved in SDS-PAGE and 
transferred to Nitrocellulose membrane. Blots were blocked using AquaBlock buffer 
(EastCoast Bio #PP82) and probed with the primary antibodies in blocking buffer + 0.1% 
Tween-20. Additional antibodies binding to Paxillin, pPaxillin Y31, Tubulin, Yap/Taz, Fak, 
pFak, Akt, pAkt, pErk, c-Met, pc-Met, Rac1, PAK, phospho-PAK, phosphor-MEK, and 
MEK were also utilized. Blots were developed by using Alexa Fluor 680 (Invitrogen 
A21058) and Alexa Fluor 790 (Invitrogen A11369) diluted in 1:20000 blocking buffer + 
0.1 % Tween 20. Blots were observed using a LI-COR Odyssey blot imager (LI-COR 
 Biosciences). The licor blot imager quantified each blot and differences in the relative 
expression level specific signaling proteins were tested for significance using ANOVA. 
 
 
Results 
Loss of Rho signaling in the A375 cell line promotes resistant colony formation 
when treated with vemurafenib. 
To understand the effective role of Rho signaling with vemurafenib we utilized A375 cells 
that were RNAi knockdowns of RhoAsh1 and RhoCsh2 and we compared their growth 
rate to NT control cells. At 60 days there is significant difference in population doubling 
between RhoA/RhoC Sh1&Sh2 group and NT groups, every Rho knockdown A375 line 
has at least double the NT group population (Fig.1A). A dose response growth inhibition 
assay was utilized in order to find a concentration of fasudil to use for the experimental 
process that would not outright destroy A375 from a lethal dosage. 10µM was our 
selected concentration of choice  (Fig.1B). Treating cells with fasudil yields very similar 
results where we see emerging resistant colonies emerging faster than our only 
vemurafenib treated cells (Fig. 1C). At 18 days we can see that the vemurafenib + 
fasudil treated cells are already growing back while the vemurafenib only treated cells 
start growing back around the 33 day mark. Additionally there is a major difference at the 
65 day mark, where the vemurafenib + fasudil treated cells have more than two times 
the population doubling than the vemurafenib alone treated cells (Fig 1C.). Interestingly 
we can see that the direct inhibition of Rho kinase or inhibition of downstream target 
such as ROCK kinase hastens the emergence of resistant cells compared to cells 
treated with vemurafenib alone. 
 
 
 
Figure 1: Loss of Rho signaling in A375 cell line promotes a decreasing resistant colony formation time when treated with 
vemurafenib. A, Population doubling versus time. a, RhoA sh1 knockdown A375 cell line. b, RhoA sh2 knockdown cell 
line. c, RhoC sh1 cell line d, RhoC sh2 cell line e, NT cell line. All five line’s were grown in 3µM of vemurafenib. The cell 
populations were terminated at 60 days. B, IC50 showing tumor cell number versus fasudil concentration C, Population 
doubling versus time. a, DMSO and Fasudil treated condition’s * they are stacked directly on top of each other. b, 
Vemurafenib + Fasudil treated conditions. c, Vemurafenib treated only condition. The cell populations were terminated at 
65 days. 
 
 Short-term fasudil treatment 
leads to subtle differences in key 
Rho, BRAF, and Rac proteins. 
 
 In order to understand how fasudil 
or Rho inhibition promotes 
resistance to vemurafenib in A375 
cells we blotted for various Rho, 
BRAF, and Rac1 proteins. We 
selected pPaxillin Y31 because it 
may possibly be associated with an 
increase in Rac1 activity.17 Working 
very close with paxillin is another 
protein we blotted for named FAK. 
There is evidence that they cross 
talk and interact directly with each 
other.13 FAK’s relation to Rac1 
activity is that FAK activates Rac1.14 
Interestingly we only see a very 
small increase in FAK with 
vemurafenib + fasudil compared to 
vemurafenib alone at the 14 day 
mark but not the 4 day mark 
(Fig. 2A). At day 4 there 
appears to be no significant 
differences among 
vemurafenib only and 
vemurafenib + fasudil 
conditions (Fig 2A). Yap and 
Taz are transcription factors 
that were selected because they are thought to regulate the Hippo pathway and 
increased expression patterns have been associated with increased cell proliferation and 
epithelial–mesenchymal transition.15 Yap and Taz have some interesting differences 
among vemurafenib + fasudil and only vemurafenib treated cells. We can see that within 
the first 4 days there is no significant difference among the vemurafenib and the 
vemurafenib + fasudil treated cells. Then at 14 days out we can see an intriguing result 
vemurafenib + fasudil treated cells have almost double the Yap/Taz expression than the 
vemurafenib only cells (Fig. 2B). We utilized pMEK S298 because S298 is where PAK 
kinase phosphorylates MEK and PAK kinase functions downstream of Rac1.16 Our blot 
showed that early expression at Day 4 had no real significant differences in pMEK S298 
expression levels. As time progressed to 14 days we saw that pMEK S298 has just 
about two times the protein expression in vemurafenib + fasudil compared to 
vemurafenib only (Fig. 2B). Similar to pMEK S298 another pMEK phosphorylation site 
was selected called pMEK S217, which is a protein that is related to BRAF activity.21 Our 
results displayed that over the first 14 days there is no substantial change in pMEK S217 
activity from vemurafenib only and vemurafenib + fasudil (Fig. 2B). Another protein we 
stained for that is linked to BRAF activity is ERK. 22 We found the same results as we did 
in pMEK 217 where there were no major differences in expression during the first 14 
days (Fig. 2B). Other proteins we stained like AKT and Src are linked to Rac1 
expression. AKT level activation has shown to inhibit Rac1-GTP binding.12 On the other 
hand, increased Src levels have been associated with increased Rac1 activity.23 Looking 
A B 
Figure 2: Title A, Western blot comparing the differences among pFAK 
Y397, FAK, pAKT S473, AKT, pPaxillin Y31, Paxillin, and Src protein 
expression. Protein was loaded from cell lysates grown under DMSO, 
Fasudil, Vemurafenib, and Vemurafenib + Fasudil conditions. There are 
two time points one at 4 days and another at 14 days. We did not carry 
a DMSO or Fasudil plate to the 14 day mark. B, Is part of the same 
Western blot containing Tubulin, YAP/TAZ, pMEK S298, pMEK S217, 
MEK1, pERK ½, and ERK ½ protein expression. Lysates were from 
exact same cells as in figure 2A. 
 at our blot there really is no large differences in either AKT or Src expression during the 
first 14 days (Fig. 2A). We do see a little increase in total AKT at day 14, however since 
the active form of AKT, pAKT S473, has a virtually the same expression, this result gives 
us no supporting evidence that active AKT levels are increased significantly (Fig. 2A). 
Finally the protein tubulin was also stained for and we see very similar expression 
throughout all 14 days for all cell treated conditions (Fig. 2B). 
 
Long-term fasudil treatment may promote resistance through the up regulation of 
Yap/Taz, pPaxillinY31, Paxillin, pMEK 
S298, and pMEK S217.  
While searching for clues during the early 
stages of treatment using fasudil, we 
might gain more insight to how resistant 
mechanisms emerge through analyzing 
the cells protein expression levels at a 
later time point. There are many pieces 
within figure 3 that help us solve this 
puzzle. Starting off we see Yap/Taz, 
pPaxillin Y31, and paxillin have crucial 
differences comparing vemurafenib only- 
and vemurafenib + fasudil-treated cells. 
We can see that there is about a four 
times fold increase in each of these 
proteins in the cells treated with 
vemurafenib + fasudil (Fig. 3A). Referring 
back to Fig. 2 A and B we can see that at 
day 4 there is no real significant difference 
and towards day 14 we can see that the 
vemurafenib + fasudil treated cells start 
producing higher expression levels of 
Yap/Taz, pPaxillin Y31, and paxillin. A 
more obvious difference can be 
seen now at day 30 where 
expression of these proteins 
increased substantially. Other 
interesting information from our 
blot can be seen in AKT and 
pAKT S473 (Fig. 3A). We see 
that the trend is identical to Fig. 2A where the expression is not showing any serious 
differences in vemurafenib only and vemurafenib + fasudil. . Further information can be 
obtained by analzying pMEK S298, which now has a four times fold increase when 
comparing vemurafenib only to vemurafenib + fasudil. The other MEK protein, pMEK 
S217, displayed an increase as well when comparing the same vemurafenib and 
vemurafenib + fasudil groups to each other (Fig. 3B). Other clues can be found from 
analyzing MEK1 and pERK 1/2. At 30 days out we see no real evidence of there being 
any substantial difference in MEK1 or pERK1/2 expression between vemurafenib only 
and vemurafenib + fasudil (Fig. 3B). Additionally tubulin elicited protein expression levels 
that were almost identical in both of our conditions supporting that no drastic changes in 
tubulin occurred either (Fig 3B). 
A B 
Figure 3: Title A, Western blot comparing the differences among pAKT 
S473, AKT, YAP/TAZ, pPaxillin Y31, and Paxillin protein expression. 
Protein was loaded from cell lysates grown under Vemurafenib or 
Vemurafenib + Fasudil conditions for 30 days. B, Is part of the same 
Western blot containing pMEK S217, pMEK S298, MEK1, pERK ½, and 
tubulin protein expression. Lysates were from exact same cells as in 
figure 2A. 
 
 Fasudil overtime 
promotes 
increased 
Yap/Taz, pMEK 
S298, and pMEK 
S217. 
In order obtain a 
clear comparison of 
significant changes 
in protein 
expression from 
day 4 all the way to 
day 30, we placed 
all time points on a 
single blot The most 
critical findings can be 
seen within Yap/Taz and 
pMEK S298 protein 
expression levels. 
Specifically looking at 
Yap/Taz we can see that over time fasudil up regulates these proteins. At day 30 there is 
a very clear distinction when we see a four fold increase from vemurafenib alone to 
vemurafenib + fasudil (Fig. 4A). Tying in pMEK S298 we see that exact same trend 
where at day 30 we have a four fold increase from vemurafenib only to vemurafenib + 
fasudil (Fig. 4A). These results are directly in line with the data we received from our 
other blots (Fig. 2A/B & 3A/B). This may explain the long-term effects fasudil has on 
A375 cells heavily promoting Yap/Taz and pMEK S298 protein levels. Looking at pMEK 
S217 we can see that there is a small increase from vemurafenib alone to vemurafenib + 
fasudil, however the change in no where near as dramatic compared to pMEK S298 and 
Yap/Taz expression levels (Fig. 4A/B). Other proteins tubulin, Anti-Src, and MEK1 all 
gave very similar expression levels throughout our 30 day time line, thus their role may 
not be as significant as Yap/Tas or our pMEK proteins (Fig. 4A/B). 
 
Discussion 
 
While vemurafenib treatment initially causes BRAF mutated tumor cell drop out, it is 
unclear which cellular mechanism the resisting cells utilize in order to promote 
resistantance. Some studies have pointed towards the small family Rho GTPases as a 
key modulator of resistance.8 We now have evidence that illustrates knocking down Rho 
or downstream effectors such as ROCK promote resistance in the BRAF mutated A375 
cell line. We saw that as early as 18 days potential resistant cell colonies emerge, which 
would cut the normal resistance time of vemurafenib in half. This result gave us the 
opposite of what we initially thought and prompted us to investigate further into what 
protein expression may look like in these cells. 
 
Through analyzing relative protein concentrations of common BRAF, Rho, and Rac1 
pathway targets there is supporting data that Rho knockdown cells or inhibition of Rho 
kinase targets such as ROCK kinase, may promote resistance through increasing 
Figure 4: Title A, Western blot comparing the differences Yap/Taz, pMEK 
S298, Tubulin, and MEK1 protein expression. Protein was loaded from cell 
lysates grown under DMSO, Fasudil, Vemurafenib or Vemurafenib + 
Fasudil conditions from 4 to 30 days B, Is part of the same Western blot 
containing pMEK S217, Anti-Src, and MEK1 protein expression. Lysates 
were from exact same cells as in figure 2A. 
 
A B 
 Yap/Taz, pMEK S298, pPaxillin Y31, and pMEK S217 expression. Having increased 
regulation of Yap/Taz is known to directly promote cell resistance within BRAF mutated 
cells through actin remodeling.10 Yap and Taz have also been linked to the regulation of 
the Hippo pathway and increased expression patterns have also been associated with 
increased cell proliferation and epithelial–mesenchymal transition.15 How pPaxillin Y31 
and pMEK S298 fit in is unclear at this point, however their association with increased 
Rac1 signaling expression could possibly lead to an up regulation of cancer cell 
motility.24 Delving further into this discussion, pMEK S298 displayed similar results as 
pPaxillin Y31 and acts as downstream target of PAK kinase.16 PAK is downstream of 
Rac1, which illustrates possible Rac1 increased activity. Yet another clue can be seen 
through the slight increase in pMEK S217 expression, which is associated with 
increased BRAF activity.21 The increase in BRAF activity may also help explain why 
inhibition of Rho promotes resistance. On the other hand, since the activation of proteins 
downstream of Rac1 is much stronger, there is supporting evidence that Rac1 plays a 
larger role in promotion of resistance in our model. Strikingly pPaxillin Y31 and pMEK 
S298 both had about a four fold increase in protein expression at 30 days. Both can be 
associated with Rac1 signaling, possibly contributing to our observed increase in 
resistance. Some reports show that Rac and Rho small family GTPases have reciprocal 
actions on one another.18, 20 Therefore the down regulation of Rho can may drive 
increased activity of Rac1 in the cell and possibly explain what is happening within our in 
vitro model. In conclusion a possible explanation of our results that inhibiting Rho 
signaling promotes vemurafenib-resistant BRAF mutated cells is that inhibiting Rho may 
have increased Rac1 activity and increased Yap/Taz expression.  
  
Our working hypothesis of Rho inhibition promoting resistance in BRAF mutated cells is 
becoming clearer. Understanding signaling proteins that are upregulated in response to 
Rho inhibition has given us insight into what just may be going on mechanistically in our 
cells. Yap/Taz increased expression provided our first clue. Being linked in many other 
studies to promoting resistance we have data and results that would be directly in line 
with these other studies.10,15 Other clues to our mechanism are the increased expression 
of pPaxillin Y31 and pMEK S298. Both can be correlated with an increase in Rac1 
expression possibly showing an increase in Rac1 could relate to promotion of 
vemurafenib resistance in the BRAF mutation. This may describe how the inhibition of 
Rho directly or indirectly leads to an up regulation of Rac1 activity. Analyzing Rac1 
activation in BRAF mutated cells may be a good investigation for future research. Other 
projects report that Rac1 is a great target to inhibit in BRAF melanomas but similarly the 
exact knowledge of the mechanism it utilizes to promote resistance was unclear.19 It 
could be very beneficial to knockdown Rac1 or it’s downstream targets. We could see 
what this would do to resistance within BRAF mutated cells and also see what would 
happen with Rho activity. Another approach would be to duplicate our exact model, 
instead we could create more cell cultures using different cell lines in order to obtain cell 
lysates from multiple vemurafenib + fasudil treated cells. Then we could analyze multiple 
blots stemming from multiple cell populations. This would give more significant numbers 
and give us better statistical data to support our findings. It would be striking to find that 
4-5 cell populations all reinforce the idea of having increased Yap/Taz, pPaxillin, pMEK 
S298, and pMEK S217 expression and really help solidify exactly what proteins Rho 
inhibition up regulates. We are also interested in the possibility of creating a model with 
patient derived xenografts to see if Rho inhibition acts similarly in xenograft tissues or 
possibly extending our current model to other BRAF mutated cell lines. 
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